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Abstract 
Fluorine-18 labeled radiotracers, such as [18F]fluorodeoxyglucose, can be used as 
practical diagnostic agents in positron emission tomography (PET). Furthermore, the 
properties of pharmaceuticals can be enhanced significantly by the introduction of 
fluorine groups into their original structures, and significant progress has been made 
during the last three decades towards the development of practical procedures for the 
introduction of fluorine. The replacement of the fluorine atoms present in 
pharmaceuticals with radioactive 18F atoms is a rational approach for designing novel 
PET tracers. As a fluorine-containing pharmaceutical agent, pitavastatin has attracted 
considerable interest from researchers working in the life sciences because it can act as 
an antihyperlipidemic agent as well as being a substrate for hepatic organic anion 
transporting polypeptides (hOATP). With this in mind, it was envisaged that 
[18F]pitavastatin would be used an excellent imaging agent for hOATP, which prompted 



























synthesis of [18F]pitavastatin by the Suzuki coupling reaction of p-iodofluorobenzene 
and a quinoline boronate derivative, with the desired product being formed in a 





Positron emission tomography (PET) is an imaging technique that is mainly used for 
the diagnosis of diseases such as cancer and Alzheimer disease, although this technique 
can also be used for the evaluation of innovative therapies and drugs.[1] A large number 
of radiotracers have been developed to date using 18F, such as [18F]fluorodeoxyglucose 
([18F]FDG),[1a] [18F]Florbetapir ([18F]AV-45),[1b,c] [18F]Flutemetamol ([18F]GE-067) [1d] 
and [18F]Florbetaben ([18F]BAY94-9172),[1e] because 18F has a much longer half-life 
(109.7 min) than most of the other positron emitting radionuclides commonly 
incorporated into pharmaceutical agents, such as 11C (20 min), 13N (10 min) and 15O (2 
min). The incorporation of 18F can also be much easier to achieve than the incorporation 
of other positron emitting radionuclides with longer half-lives such as 124I (4.2 days) 
and 89Zr (78.4 h). Furthermore, a number of fluorine-containing pharmaceuticals have 
been developed during the course of the last three decades for use in clinical 
applications, where the fluorine groups were introduced to impart the appropriate 
physicochemical, drug metabolism and pharmacokinetics (DMPK) properties to the 
active agents.[2] These agents could therefore be used as potential PET tracers by the 
replacement of their 19F atoms with radioactive 18F atoms without changing any of the 
chemical or biological properties of the parent pharmaceutical. In fact, several 
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18F-containing pharmaceutical have already been synthesized via the replacement of 
their 19F atoms with 18F atoms, including [18F]flumazenil,[3a,b] [18F]xeloda[3c] and 
[18F]spiperone,[3d] which have all been used as tracers in PET imaging experiments. 
Several DMPK studies have recently been reported pertaining to the use of PET 
imaging methods and tracers to develop a deeper understanding of hepatic organic anion 
transporting polypeptides (hOATP), which play an important role in the metabolism of 
drugs in the liver, and several candidate tracers were synthesized.[4] Unfortunately, 
however, no tracers have been reported to date with potential clinical applications. The 
major difficulty associated with the development of tracers for hOATP is achieving 
selectivity for OATP1B1, which makes a significant contribution to hepatic uptake in 
humans,[4] over OATP1B3. Fortunately, however, the fluorine containing antilipidemic 
agent pitavastatin[5] is a selective substrate of OATP1B1 with a hepatic uptake clearance 
of less than 50% hepatic blood flow. It was therefore envisaged that [18F]pitavastatin 
(Figure 1) could be used as a novel PET tracer of hOATP, and this prompted us to 
design a strategy for the synthesis of this compound. 
Fluorine atoms have traditionally been incorporated into aromatic ring through 
electrophilic substitution reactions using fluorine gas. However, radiofluorination 
reactions using [18F]F2 gas typically afford fluorinated products with low levels of 
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specific radioactivity (generally less than 0.40 GBq/µmol) because the [18F]F2 used in 
these experiments is generally contaminated with non-radioactive F2 as a carrier gas.[6] 
Furthermore, the introduction of 18F atoms through nucleophilic aromatic substitution 
reactions using fluoride ions (e.g., the Balz-Schiemann reaction) requires challenging 
experimental procedures and generally affords low yields of the desired product 
(approximately 10 %) because fluoride ions are only weakly nucleophilic.[7] Based on 
these limitations, there is an urgent need for the development of a new method for the 
synthesis of 18F labeled compounds. An alternative and reliable approach to the 
synthesis of 18F labeled compounds, which is referred to as the assembling approach, 
has recently been described.[8] According to this approach, the pre-labeled unit can be 
connected to another intermediate through synthesis to provide facile access to the 
radiolabeled pharmaceutical agent. Herein, we report a novel method for the synthesis 
of [18F]pitavastatin via the Suzuki coupling reaction[9] of p-[18F]fluoroiodobenzene with 






Figure 1. Structure of [18F]pitavastatin 
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Results and Discussion 
Any potential new route for the synthesis of [18F]pitavastatin would need to 
introduce the 18F atom during the latter stages of the process because of the short 
half-life of 18F (109.7 min). For this reason, it was not possible to apply a previously 
reported route[10] for the synthesis of [18F]pitavastatin because this method would have 
required the introduction of 18F during the early stages of the synthesis (Scheme 1). The 
decision was therefore taken to establish a novel synthetic route to [18F]pitavastatin, 



































































It was envisaged that the required 18F atom could be introduced via a Suzuki 
coupling reaction between p-[18F]fluoroiodobenzene ([18F]1) and boronate 2 in the 
presence of a palladium catalyst (Scheme 2). Compound [18F]1 was prepared by the 
nucleophilic aromatic substitution reaction of 4-iodophenyldiphenylsulfonium triflate 
with a [18F]fluoride ion. Retrosynthetic analysis of boronate 2 revealed that this material 
could be synthesized from aldehyde 4, which could undergo a 
Horner-Wadsworth-Emmons reaction in the forward sense with phosphonate 3 to give 
boronate 2.[10a] Aldehyde 4 could itself be generated from 2-aminobenzonitrile (5) 
through a series of transformations involving a quinoline formation with an 































Scheme 2. Retrosynthesis of [18F]pitavastatin 
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The Friedlander reaction[11] of 2-aminobenzonitrile (5) with β-keto ester 6 was 
performed in the presence of tin (IV) chloride to give aminoquinoline 7 in good yield 
(Scheme 3). The amino group of compound 7 was converted to the corresponding 
diazonium salt, which was subjected to a Sandmeyer reaction with copper (I) bromide 
to give aryl bromide 8. Subsequent reduction of the methyl ester group in 8 with 
diisobutylaluminium hydride (DIBAL) gave alcohol 8a, which was oxidized with 






















































Scheme 3. Synthesis of the aldehyde 4 
 
The treatment of aldehyde 4 with phosphonate 3[12] yielded the desired (E)-alkene 9 
in excellent yield (Scheme 4). Unfortunately, however, the ester group in 9 underwent 
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an undesired hydrolysis reaction during the removal of the tert-butyldimethylsilyl group 
with tetrabutylammonium fluoride (TBAF). To avoid the undesired hydrolysis of the 
methyl ester, alkene 9 was treated with diluted hydrofluoric acid in MeCN to afford 
β-hydroxy ester 10 in 89% yield. Stereoselective reduction of the carbonyl group with 
diethylmethoxyborane and sodium borohydride gave the desired diol 11 as a single 
diastereomer. The subsequent reaction of diol 11 with bis(pinacolato)diboron (12) in the 
presence of a palladium catalyst gave boronate 2, which was the precursor to the Suzuki 































































Scheme 4. Synthesis of boronate 2 
 
The Suzuki coupling of 1 with 2 was investigated under a variety of different 
reaction conditions to determine the best catalyst for the transformation (Table 1). When 
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the reaction was performed in the presence of Pd(PPh3)4 and Na2CO3 in 
dimethylsulfoxide (DMSO) at 90 °C, only a trace amount of the desired product 13 was 
obtained (Table 1, entry 1). Similar poor results were also obtained when 
PdCl2(dppf)CH2Cl2 or Pd(PPh3)2Cl2 were used as the catalyst (Table 1, entries 2 and 3). 
In contrast, the use of Pd(OAc)2 in the presence of PPh3 gave a slightly better yield of 
the desired product (Table 1, entry 4). Pleasingly, the use of a combination of Pd(PPh3)4 
and PdCl2(dppf)CH2Cl2 or Pd2(dba)3 alone yielded the coupling product in 50 and 63% 
yields, respectively. These results therefore demonstrated that we had successfully 
established a novel route for the synthesis of pitavastatin, which could be used for the 




































Entry  Catalyst 
Conditions 
Yield (%)b 
Solvent Temp. (°C) Time (h) 
1 Pd(PPh3)4 DMSO 90 9 < 10 
2 PdCl2(dppf)CH2Cl2 DMSO 90 9 < 10 
3 Pd(PPh3)2Cl2 DMSO 90 9 < 10 
4 Pd(OAc)2/PPh3 DMSO 90 9 29 
5 Pd(PPh3)4/PdCl2(dppf)CH2Cl2 DMSO 90 9 50 
6 Pd2(dba)3 DMSO 90 9 63 
















With our newly developed route in hand, we proceeded to investigate the synthesis of 
[18F]1 so that it could be used to complete the synthesis of the target molecule, 
[18F]pitavastatin. Compound [18F]1 was synthesized according to the Lehmann 
method.[13] Namely, a mixture of 4-iodophenyldiphenyl-sulfonium triflate, [18F]KF and 
K2CO3 in MeCN was heated under microwave irradiation at 120 °C in the presence of 


























Scheme 6. Synthesis of [18F]1 from 4-iodophenyldiphenylsulfonium triflate 
 
The Suzuki coupling reaction of [18F]1 with boronate 2 was investigated under a 
variety of different conditions to identify the optimum conditions for the transformation 
(Table 2). Considering the relatively short half-life of 18F, the heating time was limited 
to 10 min. Moreover, the reaction was performed in a tightly sealed tube, which was 
heated on a heating block at 100 °C to avoid the spread of the radioisotope in the 
surrounding area. Unfortunately, the optimum reaction conditions developed above for 
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the Suzuki reaction of unlabeled 1 (i.e., DMSO, Pd2(dba)3 and Na2CO3) were not 
suitable for the synthesis of the radioactive compound. Changing the solvent from 
DMSO to dimethylformamide (DMF) or MeCN had very little impact on the outcome 
of the reaction, with the product being obtained in low yield (Table 2, entries 2 and 3). 
Pleasingly, the use of Cs2CO3 instead of Na2CO3 led to an increase in the yield of the 
product (Table 2, entries 4–6). It is noteworthy that the methyl ester in [18F]13 
underwent a spontaneous hydrolysis reaction following the coupling reaction or during 
the work-up procedure to yield [18F]pitavastatin when Cs2CO3 was used as the base. In 
practice, the optimum conditions for the coupling reaction were determined to be 
Pd2(dba)3 and Cs2CO3 in MeCN at 100 °C for 10 min (Table 2, entry 9). The conditions 
gave [18F]pitavastatin in a chemical yield of 63 ± 2% and a RCY of 28 ± 3% following 

































MWb Yield (%)c 
Solvent Temp. (°C) 
1 Na2CO3 DMSO 100 – < 5 
2 Na2CO3 MeCN 100 – 13 ± 1 
3 Na2CO3 DMF 100 – 26 ± 9 
4 Cs2CO3 DMSO 100 – 20 ± 2 
5 Cs2CO3 MeCN 100 – 56 ± 7 (18 ± 4)d 
6 Cs2CO3 DMF 100 – 69 ± 1 (< 10)d 
7 Cs2CO3 MeCN 80 – 51 ± 6 
8 Cs2CO3 MeCN 120 – 51 ± 3 
9 Cs2CO3 MeCN 100 + 63 ± 2 (28 ± 3)d 
a Catalyst: 1.0 mg, base: 4.0 mg, solvent: 100 µL, [18F]1: 370–740 kBq,2: 2.0 mg. b MW power: 50 
W, reaction time: 1 min. c Summed yield of [18F]13 and [18F]pitavastatin determined by radio-HPLC. 
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Data are the mean ± S.D. (n = 3). d Isolated yield of [18F]pitavastatin (Radiochemical yield). All 
reactions were carried out in a sealed reaction vessel on an aluminum block heater.  
 
As a result, [18F]pitavastatin was obtained in a radiochemical yield of 12 ± 3 % 
(decay corrected from [18F]fluoride ion) (Scheme 7). The identity of the radiotracer was 
confirmed by RP-HPLC following its co-injection with the non-radiolabeled reference 


























































   
 
 
Figure 2. Analytical RP-HPLC chromatograms of [18F]pitavastatin co-injected with 
non-radiolabeled pitavastatin. The UV spectra were recorded at 254 nm. The peak at 12.385 min 










In summary, we developed a novel route for the synthesis of pitavastatin using a 
Suzuki coupling reaction as the key step to allow for the late stage incorporation of 18F. 
Using this route, we successfully synthesized [18F]pitavastatin in good yield by the 
Suzuki coupling of boronate 2 with p-[18F]fluoroiodobenzene under microwave heating 
conditions in the presence of Pd2(dba)3 and Cs2CO3. This Suzuki coupling strategy 
represents a useful method for the indirect 18F labeling of pharmaceuticals that could be 
applied to the synthesis of other PET tracers. The in vivo evaluation of [18F]pitavastatin 
using PET is currently underway in our laboratory, and the results of these experiments 








All of the reagents and solvents used in the current study were purchased from Wako 
Pure Chemical Industries (Tokyo, Japan), Nacalai Tesque (Kyoto, Japan), Merck 
(Darmstadt, Germany) and Sigma Aldrich (St. Louis, MO, USA), and used without 
purification. Optical rotations were measured on an AUTOPOL IV system (Rudolph 
Research Analytical, Hackettstown, NJ, USA). 1H NMR spectra were recorded on a 
JEOL ECA-500 spectrometer (JEOL, Tokyo, Japan) and the peaks referenced relative to 
the residual CHCl3 signal. Chemical shifts have been reported in parts per million (ppm) 
using the residual solvent peak as an internal standard. The 1H NMR spectra have been 
tabulated as follows: chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = 
triplet, quint = quintet, sept = septet, m = multiplet), number of protons and coupling 
constant (J). LRMS and HRMS analyses were conducted on JEOL JMS-SX 102A QQ 
and JEOL JMS-GC-mate mass spectrometer systems, respectively. Purifications by 
column chromatography were conducted over silica gel 60N (mesh size 63–210 µm; 
Kanto Chemical Co., Inc., Tokyo, Japan). Thin-layer chromatography (TLC) was 
performed using Merck silica gel F-254 aluminum plates, which were visualized under 
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UV light (254 nm). High performance liquid chromatography (HPLC) purifications and 
analyses were performed on a Shimadzu system (LC-10AT pump with an SPD-10A UV 
detector operating at 220 and 254 nm, Shimadzu Corporation, Kyoto, Japan) equipped 
with Cosmosil 5C18-ARII columns (10 × 250 mm and 4.6 × 150 mm, respectively; 
Nacalai Tesque Inc., Kyoto, Japan) and a radioisotope detector. Experiments conducted 
under microwave heating conditions were performed in a resonant-type microwave 
reactor, which was developed by SAIDA Inc. (Shizuoka, Japan).[14] 
 
Methyl (4-amino-2-cyclopropylquinolin-3-yl)carboxylate (7) 
β-Keto ester 6 (16.6 g, 140 mmol) and tin (IV) chloride (73.3 g, 281 mmol) were slowly 
added to a solution of 2-aminobenzonitrile (5) (20.0 g, 140 mmol) in toluene (280 mL) 
under an argon atmosphere at 15 °C, and the resulting mixture was heated at reflux for 3 
h. The reaction was then cooled to room temperature and diluted with a saturated 
aqueous solution of Na2SO4 before being cooled to 0 °C. The resulting precipitate was 
crushed into smaller pieces and filtered, and the filtrate was extracted with EtOAc. The 
organic layer was washed with brine and dried over MgSO4 before being concentrated 
in vacuo to give aminoquinoline 7 as a purple solid (28.5 g, 83.9 %). 
1H NMR (500 MHz, CDCl3) δ: 7.79 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.59 
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(t, J = 8.3 Hz, 1H), 7.31 (t, J = 8.3 Hz, 1H), 6.64 (br, 2H), 3.95 (s, 3H), 2.62 (tt, J = 8.0, 
4.9 Hz, 1H), 1.24 (qd, J = 4.9, 2.6 Hz, 2H), 0.94 (dq, J = 8.0, 2.6 Hz, 2H); 13C NMR 
(125 MHz, CDCl3): δ 170.0, 161.9, 152.3, 147.7, 130.8, 129.2, 124.4, 120.4, 116.6, 
103.5, 51.7, 17.2, 9.4 (2C); MS (EI) m/z: 242 (M+, 100), 214 (98), 209 (76), 183 (86), 
171 (30), 154 (28); HRMS calcd for C14H14N2O2 (M+): 242.1055, found 242.1060. 
 
Methyl (4-bromo-2-cyclopropylquinolin-3-yl)carboxylate (8) 
Copper (I) bromide (29.5 g, 206 mmol) and tert-butyl nitrite (18.2 g, 176 mmol) were 
slowly added to a solution of aminoquinoline 7 (28.5 g, 117 mmol) in MeCN (280 mL) 
under an argon atmosphere at 15 °C, and the resulting mixture was stirred at 40 °C for 
2.5 h. The mixture was then cooled to room temperature and stirred for overnight. The 
reaction mixture was diluted with a saturated aqueous solution of Na2SO4, and the 
resulting precipitate was removed by filtration. The filtrate was extracted with EtOAc, 
and the organic layer was washed with brine and dried over MgSO4. The solvent was 
then removed under reduced pressure to give a residue, which was purified by column 
chromatography over silica gel eluting with a 20:1 (v/v) mixture of n-hexane and 
EtOAc to give bromide 8 as an orange solid (20.9 g, 58.0 %). 
1H NMR (500 MHz, CDCl3) δ: 8.11 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.68 
(t, J = 8.3 Hz, 1H), 7.52 (t, J = 8.3 Hz, 1H), 4.05 (s, 3H), 2.06 (tt, J = 8.0, 4.6 Hz, 1H), 
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1.24 (qd, J = 4.6, 2.9 Hz, 2H), 0.94 (dq, J = 8.0, 2.9 Hz, 2H); 13C NMR (125 MHz, 
CDCl3): δ 167.8, 158.7, 150.8, 130.8, 130.7, 130.4, 129.2, 127.0, 126.9, 125.1, 53.0, 
15.8, 10.7 (2C); MS (EI) m/z: 307 (M+2, 66), 305 (M+, 68), 277 (100), 262 (39), 246 




A 1.0 M solution of DIBAL in n-hexane (20.8 mL, 20.8 mmol) was added to a solution 
of bromide 8 (3.19 g, 10.4 mmol) in toluene (20.0 mL) under an argon atmosphere at 
0 °C, and the resulting mixture was stirred for 1 h at room temperature. The reaction 
was then cooled to 0 °C and quenched by the addition of a 5 % solution of H2SO4. The 
resulting mixture was extracted with EtOAc, and the organic layer was washed with 
brine and dried over MgSO4. The solvent was then removed under reduced pressure to 
give alcohol 8a as a brown solid (2.30 g). 
1H NMR (500 MHz, CDCl3) δ: 8.10 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.64 
(t, J = 7.5 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 5.23 (s, 2H), 2.53 (tt, J = 8.0, 4.2 Hz, 1H), 
2.27 (br, 1H), 1.29 (qd, J = 4.2, 3.1 Hz, 2H), 1.06 (dq, J = 8.2, 3.1 Hz, 2H); 13C NMR 
(125 MHz, CDCl3) δ: 162.1, 147.8, 136.2, 131.6, 130.0, 129.0, 127.3, 126.7, 126.3, 62.4, 
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14.2, 11.5 (2C); MS (EI) m/z: 279 (M+2, 87), 277 (M+, 89), 260 (100), 248 (24), 179 
(37), 167 (49); HRMS calcd for C13H12BrNO (M+): 277.0102, found 277.0096. 
Dess-Martin periodinane (1.68 g, 3.95 mmol) was added to a solution of alcohol 8a 
(1.00 g, 3.60 mmol) in CH2Cl2 (20.0 mL) under an argon atmosphere at 0 °C, and the 
resulting mixture was stirred for 3 h at room temperature. The reaction was then 
quenched by the addition of a saturated aqueous solution of NaHCO3, and the resulting 
mixture was extracted with EtOAc. The organic layer was washed sequentially with a 
saturated aqueous solution of NaS2O3 and brine and dried over MgSO4. The solvent was 
then removed under reduced pressure to give a residue, which was purified by column 
chromatography over silica gel eluting with a 10:1 (v/v) mixture of n-hexane and 
EtOAc to give aldehyde 4 as a colorless solid (830 mg, 83.6 % in 2 steps). 
1H NMR (500 MHz, CDCl3) δ: 10.7 (s, 1H), 8.25 (d, J = 8.2 Hz, 1H), 7.89 (d, J = 8.2 
Hz, 1H), 7.76 (t, J = 8.2 Hz, 1H), 7.56 (t, J = 8.2 Hz, 1H), 3.02 (tt, J = 8.2, 4.2 Hz, 1H), 
1.24 (qd, J = 4.2, 3.1 Hz, 2H), 0.94 (dq, J = 8.2, 3.1 Hz, 2H); 13C NMR (125 MHz, 
CDCl3) δ: 194.0, 162.1, 149.0, 140.8, 132.5, 129.2, 127.2, 127.0, 126.8, 125.5, 14.2, 
11.5 (2C); MS (EI) m/z: 277 (M+2, 8.6), 275 (M+, 8.6), 247 (100), 196 (1.3), 168 (2.8); 




Methyl (3R, 6E)-7-(4-bromo-2-cyclopropylquinolin-3-yl)-3-(tert-butyldimethyl- 
silyloxy)-5-oxohept-6-enoate (9) 
A solution of phosphonate 3 (7.00 g, 18.3 mmol) in THF (48.0 mL) was added to a 
suspension of sodium hydride (0.730 g, 18.2 mmol, 60 % dispersion in mineral oil) in 
THF (12.5 mL) under an argon atmosphere at 0 °C, and the resulting mixture was 
stirred for 1 h at 0 °C. A solution of aldehyde 4 (4.81 g, 17.4 mmol) in THF (75.0 mL) 
was then added to the reaction at 0 °C, and the resulting mixture was stirred for 
overnight at room temperature. The reaction was then quenched by the addition of a 
saturated aqueous solution of NH4Cl, and the resulting mixture was extracted with 
EtOAc. The organic layer was washed with brine and dried over Na2SO4. The solvent 
was removed under reduced pressure to give a residue, which was purified by column 
chromatography over silica gel eluting with a 5:1 (v/v) mixture of n-hexane and EtOAc 
to give alkene 9 as a yellow oil (8.57 g, 92.5 %). 
1H NMR (500 MHz, CDCl3) δ: 8.16 (d, J = 8.3 Hz, 1H), 7.91 (d, J = 16.3 Hz, 1H), 7.90 
(d, J = 8.3 Hz, 1H), 7.68 (t, J = 8.3 Hz, 1H), 7.53 (t, J = 8.3 Hz, 1H), 6.71 (d, J = 16.3 
Hz, 1H), 4.76 (m, 1H), 3.70 (s, 3H), 3.06 (dd, J = 15.8, 6.9 Hz, 1H), 2.97 (dd, J = 15.8, 
5.7 Hz, 1H), 2.65 (dd, J = 14.7, 5.7 Hz, 1H), 2.59 (dd, J = 14.7, 6.3 Hz, 1H), 2.30 (tt, J 
= 8.0, 4.6 Hz, 1H), 1.35 (dq, J = 4.6, 3.0 Hz, 2H), 1.05 (dq, J = 8.0, 3.0 Hz, 2H), 0.85 (s, 
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9H), 0.10 (s, 3H), 0.09 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 197.5, 171.4, 160.1, 
147.5, 140.4, 135.0, 134.7, 130.5, 129.8, 129.1, 127.0 (2C), 126.9, 125.9, 66.1, 51.5, 
48.2, 42.5, 25.7 (3C), 17.9, 16.5, 11.0, –4.7, –4.9; MS (CI) m/z: 534 (M+2, 100), 532 
(M+, 96), 474 (50), 400 (39), 320 (32), 217 (39), 133 (41), 75 (41); HRMS calcd for 
C26H34BrNO4Si (M+): 532.1518, found 532.1515; [α]20D: +1.685 (c 0.99, MeOH). 
 
Methyl (3R, 6E)-7-(4-bromo-2-cyclopropylquinolin-3-yl)-3-hydroxy-5-oxohept-6- 
enoate (10) 
A 1:19 (v/v) solution of 48% hydrofluoric acid in MeCN (4.00 mL) was added to a 
solution of alkene 9 (400 mg, 0.751 mmol) in MeCN (1.00 mL) at 0 °C, and the 
resulting mixture was stirred for 19 h at room temperature. The reaction was then 
quenched by the addition of an aqueous solution of NaHCO3, and the resulting mixture 
was extracted with EtOAc. The organic layer was washed with brine and dried over 
MgSO4. The solvent was removed under reduced pressure to give a residue, which was 
purified by column chromatography over silica gel eluting with a 2:1 (v/v) mixture of 
n-hexane and EtOAc to give β-hydroxy ester 10 as a yellow solid (280 mg, 89.1 %). 
1H NMR (500 MHz, CDCl3) δ: 8.15 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 16.6 Hz, 1H), 7.90 
(d, J = 8.3 Hz, 1H), 7.68 (t, J = 8.3 Hz, 1H), 7.53 (t, J = 8.3 Hz, 1H), 6.71 (d, J = 16.6 
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Hz, 1H), 4.65 (br, 1H), 3.74 (s, 3H), 3.53 (br, 1H), 3.05 (dd, J = 17.1, 7.4 Hz, 1H), 3.00 
(dd, J = 17.1, 4.4 Hz, 1H), 2.65 (d, J = 6.6 Hz, 2H), 2.28 (tt, J = 8.0, 4.6 Hz, 1H), 1.35 
(dq, J = 4.6, 3.1 Hz, 2H), 1.05 (dq, J = 8.0, 3.1 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 
198.6, 172.2, 160.1, 147.5, 141.0, 134.8, 134.4, 130.6, 129.5, 129.0, 127.0 (2C), 125.8, 
64.5, 51.5, 46.4, 40.6, 16.5, 11.0 (2C); MS (EI) m/z: 419 (M+2, 0.1), 417 (M+, 0.1), 315 
(22), 236 (100), 102 (3.0), 74 (3.0); HRMS calcd for C20H20BrNO4 (M+): 417.0575, 
found 417.0583; [α]20D : –7.727 (c 0.99, MeOH). 
 
Methyl (3R, 5S, 6E)-7-(4-bromo-2-cyclopropylquinolin-3-yl)-3,5- 
dihydroxyhept-6-enoate (11) 
A 1.0 M solution of diethylmethoxyborane in THF (10.8 mL, 10.8 mmol) was added to 
a solution of β-hydroxy ester 10 (4.03 g, 9.63 mmol) in THF (30.0 mL) and MeOH 
(6.00 mL) at –78 °C, and the resulting mixture was stirred for 20 min at –78 °C. Sodium 
borohydride (452 mg, 10.7 mmol) was then added to the reaction mixture at –78 °C, and 
the resulting mixture was stirred for 1 h at –78 °C. The reaction was then quenched by 
the addition of a solution of AcOH (5.70 mL) in EtOAc (27.0 mL), and the resulting 
mixture was stirred for 3 h at room temperature. The mixture was poured into a 
saturated aqueous solution of NaHCO3, and the resulting mixture was extracted with 
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EtOAc. The organic layer was washed with brine and dried over MgSO4 before being 
concentrated under reduced pressure. The resulting residue was purified by column 
chromatography over silica gel eluting with a 1:1 (v/v) mixture of n-hexane and EtOAc 
to give diol 11 as a yellow solid (2.93 g, 72.0 %). 
1H NMR (500 MHz, CDCl3) δ: 8.13 (d, J = 8.0 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.63 
(t, J = 8.2 Hz, 1H), 7.49 (t, J = 8.2 Hz, 1H), 6.87 (dd, J = 16.0, 1.1 Hz, 1H), 6.09 (dd, J 
= 16.0, 5.7 Hz, 1H), 4.73 (br, 1H), 4.42 (br, 1H), 3.81 (s, 1H), 3.73 (s, 3H), 3.63 (s, 1H), 
2.57 (dd, J = 6.8, 1.7 Hz, 2H), 2.42 (tt, J = 8.0, 4.6 Hz, 1H), 1.91−1.80 (m, 2H), 1.29 (dd, 
J = 4.6, 2.6 Hz, 2H), 1.01 (dq, J = 8.0, 2.6 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 
172.9, 160.9, 147.0, 140.0, 133.8, 131.8, 129.5, 127.0 (2C), 126.6, 126.5, 126.2, 72.4, 
68.4, 51.9, 42.4, 41.4, 16.4, 10.7 (2C); MS (EI) m/z: 421 (M+2, 3.2), 419 (M+, 3.3), 383 
(7.5), 340 (38), 298 (45), 274 (100), 220 (56); HRMS calcd for C20H22BrNO4 (M+): 
419.0732, found 419.0729; [α]20D: +22.858 (c 1.00, MeOH). 
 
Methyl (3R, 5S, 6E)-7-{2-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3- 
dioxabolan-2-yl)quinolin-3-yl}-3,5-dihydroxyhept-6-enoate (2) 
PdCl2(dppf)CH2Cl2 (0.19 g, 0.240 mmol) was added to a stirred solution of diol 11 
(1.00 g, 2.40 mmol), bis(pinacolato)diboron (12) (0.790 g, 3.12 mmol) and K2CO3 (1.00 
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g, 7.20 mmol) in DMSO (40.0 mL) under an argon atmosphere, and the resulting 
mixture was stirred for 4 h at 70 °C. Silica gel was then added to the reaction, and the 
resulting mixture was filtrated through Celite. The filtrate was extracted with EtOAc 
and the organic layer was washed sequentially with water and brine before being dried 
over Na2SO4. The solvent was then concentrated under reduced pressure to give a 
residue, which was subjected to azeotropic dehydration with MeCN and purified by 
HPLC (Shimadzu system equipped with a Cosmosil 5C18-ARII 10 × 250 mm column, 
MeCN/water = 50/50, flow rate = 5.0 mL/min) to afford a brown oil. Powderization of 
the resulting oil with a 1:1 (v/v) mixture of diisopropyl ether and n-heptane gave 
boronate 2 as a pale yellow solid (0.290 g, 25.9 %). 
1H NMR (500 MHz, CDCl3) δ: 7.91 (d, J = 9.2 Hz, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.56 
(t, J = 9.2 Hz, 1H), 7.40 (t, J = 9.2 Hz, 1H), 7.19 (dd, J = 16.0, 1.4 Hz, 1H), 6.03 (dd, J 
= 16.0, 5.4 Hz, 1H), 4.66 (br, 1H), 4.38 (br, 1H), 3.75 (br, 1H), 3.73 (s, 3H), 3.32 (br, 
1H), 2.56 (d, J = 3.4 Hz, 1H), 2.54 (s, 1H), 2.28 (tt, J = 8.0, 4.6 Hz, 1H), 1.87 - 1.78 (m, 
2H), 1.46 (s, 12H), 1.25–1.20 (m, 2H), 0.98 (dd, J = 8.0, 3.1 Hz, 2H); 13C NMR (125 
MHz, CDCl3): δ 172.9, 159.6, 146.3, 138.2, 135.6, 129.2, 128.9 (2C), 128.4, 127.2 (2C), 
125.4, 84.7 (2C), 72.4, 68.5, 51.9, 42.7, 41.3, 25.3 (2C), 25.2 (2C), 15.4, 9.5, 9.3; MS 
(EI) m/z: 467 (M+, 6.8), 346 (100), 322 (80), 220 (92), 206 (57); HRMS calcd for 
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C26H34BNO6 (M+): 467.2479, found 467.2481; [α]20D: +22.932 (c 1.00, MeOH). 
  
Methyl (3R, 5S, 6E)-7-{2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl}-3,5- 
dihydroxyhept-6-enoate (13) 
Pd(PPh3)4 (9.10 mg, 0.00789 mmol) and PdCl2(dppf)CH2Cl2(6.20 mg, 0.00789 mmol) 
were added to a solution of 2 (37.0 mg, 0.0788 mmol), 4-fluoroiodobenzene (26.2 mg, 
0.118 mmol), and Na2CO3 (25.0 mg, 0.236 mmol) in DMSO (40.0 mL) under an argon 
atmosphere, and the resulting mixture was stirred for 9 h at 90 °C. The mixture was then 
cooled to room temperature, poured into water and extracted with EtOAc. The organic 
layer was washed with brine and dried over Na2SO4 before being concentrated under 
reduced pressure. The resulting residue was subjected to azeotropic dehydration with 
MeCN and purified by HPLC (Shimadzu system with a Cosmosil 5C18-ARII 10 × 250 
mm column, MeCN/water = 70/30, flow rate = 5.0 mL/min) to give methyl ester 13 as 
an amorphous solid (3.00 mg, 8.80 % (isolated yield)). 
1H NMR (500 MHz, CDCl3) δ: 7.95 (d, J = 8.3 Hz, 1H), 7.59 (t, J = 8.3 Hz, 1H), 7.35–
7.28 (m, 2H), 7.24–7.13 (m, 4H), 6.63 (dd, J = 16.0, 1.4 Hz, 1H), 5.58 (dd, J = 16.0, 6.3 
Hz, 1H), 4.40 (m, J = 2.6 Hz, 1H), 4.15–4.10 (m, 1H), 3.60 (br, 1H), 3.73 (s, 3H), 3.10 
(br, 1H), 2.50–2.36 (m, 3H), 1.50 (ddd, J = 9.2, 4.0, 1.1 Hz, 1H), 1.37–1.30 (m, 3H), 
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0.98 (dd, J = 8.0, 2.3 Hz, 2H); 13C NMR (125 MHz, CDCl3): δ 172.9, 162.2 (d, JF = 
246.5 Hz), 161.2, 160.7, 146.8, 144.2, 139.7, 133.5, 131.8 (dd, JF = 28.8, 7.8 Hz) (2C), 
129.3, 128.9, 126.1, 126.0, 125.8, 125.4, 115.3 (dd, JF = 21.6, 3.3 Hz) (2C), 72.4, 68.0, 
51.9, 42.3, 41.2, 15.9, 10.3, 10.2; MS (EI) m/z: 435 (M+, 5.2), 314 (56), 280 (100), 274 
(70), 220 (14); HRMS calcd for C26H26FNO4 (M+): 435.1846, found 435.1849; [α]20D: 
+35.707 (c 0.68, MeOH). 
 
(3R, 5S, 6E)-7-[2-cyclopropyl-4-{4-fluorophenyl}quinolin-3-yl]-3,5-dihydroxyhept- 
6-enoic acid (pitavastatin) 
A 1.0 M aqueous solution of NaOH (1 mL) was added to a solution of 13 (3 mg, 6.9 
µmol) in methanol (1 mL) at room temperature, and the resulting mixture was stirred for 
30 min at the same temperature. The reaction mixture was then concentrated under 
reduced pressure to give pitavastatin (sodium salt) as a colorless oil (3 mg, quant.). 
1H NMR (500 MHz, DMSO-d6) δ: 7.83 (d, J = 8.3 Hz, 1H), 7.60 (t, J = 8.3 Hz, 1H), 
7.36–7.23 (m, 6H), 6.48 (d, J = 16.0 Hz, 1H), 5.80 (br, 1H), 5.57 (dd, J = 16.0, 5.5 Hz, 
1H), 4.93 (br, 1H), 4.13 (m, 1H), 3.65 (br, 1H), 3.40 (m, 4H), 2.08 (d, J = 12.0 Hz, 1H), 
1.95 (dd, J = 15.5, 8.6 Hz, 1H), 1.40 (dt, J = 14.3, 7.8 Hz, 1H), 1.20–1.00 (m, 5H); 13C 
NMR (125 MHz, DMSO-d6) δ: 178.5, 161.6, 160.6, 144.8, 142.2, 133.1 (2C), 132.0 (dd, 
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JF = 37.4, 8.0 Hz) (2C), 129.6, 128.8, 128.3, 125.7, 125.6 (2C), 123.1, 115.2 (dd, JF = 
21.0, 9.3 Hz) (2C), 68.9, 65.6, 44.2, 40.0, 15.3, 10.7 (2C); MS (FAB+) m/z: 444 (M+); 




[18F]Fluoride was produced by cyclotron (CYPRIS HM-18, Sumitomo Heavy Industries, 
Tokyo, Japan) via an 18O (p,n) 18F reaction and passed through a Sep-Pak Light QMA 
cartridge (Waters Corporation, Milford, MA, USA) as an aqueous solution in 
18O-enriched water. The cartridge was dried under a stream of N2 and the 18F activity 
was eluted with 1.00 mL of a Kryptofix2.2.2 (Merck)/K2CO3 solution (9.50 mg of 
Kryptofix2.2.2 and 1.70 mg of K2CO3 in 96:4 (v/v) mixture of MeCN and water). The 
solvent was removed by azeotropic dehydration with MeCN (1.00 mL) at 120 °C under 
a stream of argon gas over 10 min. 
 
Synthesis of p-[18F]fluoroiodobenzene ([18F]1) from 4-iodophenyldiphenyl- 
sulfonium triflate 
A solution of 4-iodophenyldiphenylsulfonium triflate (2.00 mg) in MeCN (150 µL) was 
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added to a reaction vessel containing the 18F activity (1.10 – 1.50 GBq), and the reaction 
was heated for 1 min under microwave irradiation (50.0 W), The resulting mixture was 
cooled for 1 min and then passed through a Sep-Pak Light C18 column (Waters) and 
washed with water (10 mL). A stream of N2 gas was passed over the column for 10 sec, 
and p-[18F]fluoroiodobenzene ([18F]1) was eluted with MeCN (500 µL). The eluent 
containing [18F]1 was determined to be purified by HPLC analysis (RCY 56.2 ± 3.1 % 
decay corrected, data are the mean ± SD (n = 3)). 
 
Synthesis of [18F]pitavastatin using Suzuki coupling reaction with [18F]1 
A solution of [18F]1 in MeCN (37.0–74.0 MBq, 100 µL) was added to a solution of 2 
(2.0 mg), Pd2(dba)3 (1.00 mg) and Cs2CO3 (4.00 mg) in MeCN (100 µL), and the 
resulting  mixture was heated to 100 °C under microwave irradiation (50.0 W) for 1 
min. The mixture was then passed through a COSMONICE(R) Filter (S) (0.45 µm, 
4mm) and purified by preparative HPLC [Cosmosil 5C18-ARII 10 × 250 mm column, 
MeOH/20 mM phosphate buffer (pH 2.5) = 70/30, flow rate 5.0 mL/min] to give a 
solution of pure [18F]pitavastatin (Rt = 8.53 min, 12.1 ± 3.0 % RCY from [18F]fluoride 
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